Molecular testing of rectal cancer after short-course radiation
Part of Cancer, Digestive system clinical trials.
This study looks at molecular (tumor biology) features of rectal cancer in people receiving standard short-course radiation. Your tissue and/or samples may be used to better understand the cancer and how it responds to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed rectal adenocarcinoma (a type of rectal cancer)
- You are age 18 or older
- Your rectal cancer has not spread to distant organs (no distant metastases)
- You have no prior radiation to the pelvis and no prior chemo or surgery specifically for rectal cancer
- Your cancer must be planned for total mesorectal excision (a surgical approach for rectal cancer that aims for clean margins)
- If you can become pregnant, you must have a recent negative pregnancy test and agree to effective birth control during the study and for a short time after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a short course of radiation given before chemotherapy for people with locally advanced rectal cancer (cancer that has grown into nearby tissue and/or nearby lymph nodes but can still be removed). It may help shrink the tumor and make treatment more effective while assessing how well this approach works.
This study tests a new combination of treatment before surgery for high-risk rectal cancer. It combines a shorter course of radiation with chemotherapy and immunotherapy (which helps your immune system fight cancer) to see if it shrinks the tumor and improves outcomes.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests whether combining chemotherapy (mFOLFOX6) and a short course of radiation before surgery improves outcomes for people with resectable rectal cancer. The goal is to shrink and control the cancer early and then remove it with curative surgery.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This study compares two different schedules of radiation (a short course versus a longer course) followed by standard chemotherapy and immunotherapy for advanced rectal cancer. It aims to see which approach works best to shrink the tumor before surgery.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.